A controlled, double-blind study using pemo-line and placebo in the management of hyper-kinetic behavior associated with minimal brain dysfunction is described. Improvement in gross behavior as measured by parent, teacher and physician global evaluations, as well as improve-ment in cognitive and perceptual function as measured by psychological tests, is recorded for the pemoline group. This was achieved with minimal side effects on a once-daily dosage regimen, indicating that pemoline is a highly useful clinical alternative to the amphetamines and methylphenidate as an adjunct in the management of hyperkinetic behavior.
Get full access to this article
View all access options for this article.
References
1.
Conners, C. K.: The syndrome of minimal brain dysfunction: psychological aspects. Pcdiat. Clin. N. Amer., 1967, 14, 749.
2.
Conners, C. K.: Recent drug studies with hyperkinetic children. J. Learning Disabil., 1971, 44, 14.
3.
Conners, C. K.: II. Psychological effects of stimulant drugs in children with minimal brain dysfunction. Pediatrics, 1972, 49, 702.
4.
Conners, C. K., et al.: Magnesium pemoline and Dextroamphetamine: A controlled study in chil-dren with minimal brain dysfunction. Psychop-pharmacologia (Berlin), 1972, 26, 321.
5.
Millichap, J. G., & Fowler, G.: Treatment of “minimal brain dysfunction” syndromes. Pediat. Clin. N. Amer., 1967, 14, 767.
6.
Schmidt, L.: 5-phenyl-2-imino-4-oxo-oxazolidine, a central stimulant. Arzneimittelforschung, 1956, 6, 423.
7.
Wender, P. H.: Minimal Brain Dysfunction in Children. New York: Wiley-Interscience, 1971.
